NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies

NRG Therapeutics develops oral small-molecule drugs targeting mitochondrial dysfunction, aiming to slow or halt neurodegenerative diseases such as ALS and Parkinson’s through disease-modifying treatments.